• Clinical Trials - Age related macular degeneration

    Study Objective Contact
    A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY [LCID Study Number: 2017-005] The purpose of this study is to compare the effects, good or bad, of lampalizumab, administered to patients by intravitreal injection (an injection into your eye), on you and your Geographic Atrophy (GA), a form of dry age-related macular degeneration (AMD). In this open label extension study, you will receive lampalizumab by intravitreal injection either every 4 weeks (Q4W) or every 6 weeks (Q6W). Lampalizumab is an experimental drug, which means that health authorities (such as the FDA) have not approved lampalizumab (hereafter referred to as “study drug”) for the treatment of GA. Principal Investigator(s):
    Jeffrey Chang, MD, MMS

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.
    Protocol GX29176: A Phase III Multicenter, Randomized, Double-Masked Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration [LCID Study Number: 2014-061] The purpose of this study is to compare the effects, good or bad, of lampalizumab versus sham injection on you and your geographic atrophy (GA) and also to see if lampalizumab works differently in people with specific inherited (genetic) characteristics with an increased risk of AMD Principal Investigator(s):
    Jeffrey Chang, MD, MMS

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.
    Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration: CEDAR STUDY [LCID Study Number: 2015-058] The purpose of this study is to investigate the safety and effectiveness of an investigational drug called abicipar on patients who have been diagnosed with “wet” age related macular degeneration. The effects of this drug will be compared with another, FDA approved drug called Lucentis. Researchers will also measure the body’s immune response while on these drugs while measuring the amount of antibodies that have formed in the participant’s blood. Patients who are enrolled will come in for study visits every four weeks for the length of the study, which is approximately 24 months. Principal Investigator(s):
    Gregory R. Blaha, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.